Moderna Fundamentals

MRNA
 Stock
  

USD 155.54  5.59  3.73%   

Moderna fundamentals help investors to digest information that contributes to Moderna's financial success or failures. It also enables traders to predict the movement of Moderna Stock. The fundamental analysis module provides a way to measure Moderna's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moderna stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh
Moderna Consolidated Income is projected to increase significantly based on the last few years of reporting. The past year's Consolidated Income was at 12.2 Billion. The current year Earning Before Interest and Taxes EBIT is expected to grow to about 14.3 B, whereas Preferred Dividends Income Statement Impact is forecasted to decline to about 19.1 M.

Moderna Price to Sales Analysis

Moderna's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
 2019 2020 2021 2022 (projected)
Revenues USD60 M803 M18.47 B19.93 B
Revenues60 M803 M18.47 B19.93 B
P/S 
 = 
MV Per Share 
Revenue Per Share 
More About Price to Sales | All Equity Analysis

Current Moderna Price to Sales

    
  3.41 X  
Most of Moderna's fundamental indicators, such as Price to Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moderna is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Moderna Price to Sales Historical Pattern

Today, most investors in Moderna Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Moderna's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's price to sales growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Moderna price to sales as a starting point in their analysis.
 Moderna Price to Sales 
Share
      Timeline 
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Compare to competition

Moderna Price to Sales Ratio

Price to Sales Ratio

5.68

Share
Moderna Price to Sales Ratio is projected to increase significantly based on the last few years of reporting. The past year's Price to Sales Ratio was at 5.54
Based on the latest financial disclosure, the price to sales indicator of Moderna is roughly 3.41 times. This is 84.07% lower than that of the Healthcare sector and 96.53% lower than that of the Biotechnology industry. The price to sales for all United States stocks is 70.14% higher than that of the company.

Moderna Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Moderna's current stock value. Our valuation model uses many indicators to compare Moderna value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Moderna competition to find correlations between indicators driving Moderna's intrinsic value. More Info.
Moderna is considered to be number one stock in market capitalization category among related companies. It is considered to be number one stock in total asset category among related companies . The ratio of Market Capitalization to Total Asset for Moderna is about  8,303 . Moderna Market Capitalization is projected to increase significantly based on the last few years of reporting. The past year's Market Capitalization was at 102.98 Billion. Comparative valuation analysis is a catch-all model that can be used if you cannot value Moderna by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Moderna's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moderna's earnings, one of the primary drivers of an investment's value.

Moderna Current Valuation Drivers

We derive many important indicators used in calculating different scores of Moderna from analyzing Moderna's financial statements. These drivers represent accounts that assess Moderna's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Moderna's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(235.46 M)(359.55 M)(484 M)(651 M)13.52 B14.58 B
Earnings Before Interest Taxes and Depreciation Amortization USD(235.46 M)(359.55 M)(484 M)(651 M)13.52 B14.58 B
Earnings before Tax(256 M)(384.41 M)(515 M)(744 M)13.29 B14.33 B
Free Cash Flow(389.88 M)(436.63 M)(491 M)1.96 B13.34 B14.39 B
Invested Capital772.9 M1.11 B1.34 B531 M9.4 B10.14 B
Tangible Asset Value1.08 B1.96 B1.59 B7.34 B24.67 B26.62 B
Working Capital591.76 M1.34 B985.69 M1.91 B6.94 B7.49 B

Moderna Institutional Holders

Institutional Holdings refers to the ownership stake in Moderna that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Moderna's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Moderna's value.
Security TypeSharesValue
Baillie Gifford CoCommon Shares45.6 M7.9 B
Blackrock IncCommon Shares28.7 M4.9 B
Vanguard Group IncCommon Shares27 M4.7 B
Flagship Pioneering IncCommon Shares17.6 MB
State Street CorpCommon Shares14.8 M2.6 B
Coatue Management LlcCommon Shares6.9 M1.2 B
Geode Capital Management LlcCommon Shares6.4 M1.1 B
Susquehanna International Group LlpCall Options4.2 M716.5 M
Susquehanna International Group LlpPut Options3.9 M669.8 M

Moderna Fundamentals

About Moderna Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Moderna's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moderna using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moderna based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue6.9 B7.4 B
Cost of Revenue2.6 B2.1 B
Revenues18.5 B19.9 B
Revenue to Assets 0.75  0.81 
Revenue Per Employee6.8 M7.4 M
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics. The company has strategic alliances with AstraZeneca PLC Merck Co., Inc. Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Limited Carisma Therapeutics, Inc. Metagenomi, Inc. the Defense Advanced Research Projects Agency Biomedical Advanced Research and Development Authority Institute for Life Changing Medicines and The Bill Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moderna without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Content Syndication Now

   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Moderna Piotroski F Score and Moderna Altman Z Score analysis. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
2.02
Market Capitalization
59.6 B
Quarterly Revenue Growth YOY
2.13
Return On Assets
0.5
Return On Equity
1.4
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.